Videos

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.

Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.

In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.

Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.

Aparna Parikh, MD, MS, discusses how her early experiences with physical fitness shaped her current relationship with exercise.

CancerNetwork® spoke with Allyson J. Ocean, MD, Diane M. Simeone, MD, Manuel Hidalgo Medina, MD, PhD, and Andrew E. Hendifar, MD, about their recent research into the treatment of pancreatic cancer.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about keeping track of conference and journal updates to help build and maintain knowledge around lung cancer.

Zofia Piotrowska, MD, discusses the role of amivantamab in the treatment of patients with NSCLC and EGFR exon 20 insertions.

Zofia Piotrowska, MD, reviews historical treatment approaches for patients with NSCLC and EGFR exon 20 insertions.

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Considerations regarding treatment selection for patients with steroid-refractory chronic graft-vs-host disease based on current unmet needs and newer therapies in the pipeline.

Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.

Reactions to a case of chronic graft-vs-host disease and thoughts on sequencing therapy.

The best practices for treating patients with steroid-refractory chronic graft-vs-host disease, with implications for using ruxolitinib based on results of the REACH3 clinical trial.

Drs Lyudmila Bazhenova and Federico Albrecht comment on the significance of real-world data collection in EGFR-mutated non–small cell lung cancer and suggest what can be done to increase the rates of real-world studies conducted.

Best practices in determining eligibility and preparing patients with myelofibrosis for allogeneic stem cell transplantation.

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.

Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.

Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about coming research involving immunotherapy for patients with lung cancer.

David A. Braun, MD, PhD continues the first-line clinical trial discussion with the addition of KEYNOTE-426 and CLEAR trial data.

Tian Zhang, MD, MHS, and Moshe Orenstein, MD, MA, recall data from two clinical trials for first-line treatment of advanced renal cell carcinoma: CheckMate-9ER and CheckMate-214.

A prostate cancer expert reviews trial design and efficacy data with next-generation androgen receptor inhibitors.

Dr Aaron Berger discusses systemic therapy options, treatment selection and monitoring for patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Dr Morgans discusses how patient access impacts treating metastatic prostate cancer.

Alicia Morgans, MD, MPH, mentions other factors clinicians need to consider before adding PARP inhibitors to metastatic prostate cancer therapy.

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.